| Popis: |
To assess composite endpoints combining glycemic control (HbA1c7.0%, ≤6.5%, or5.7%) with weight loss (≥5%, ≥10%, or ≥15%) and without hypoglycemia with tirzepatide in type 2 diabetes (T2D).Data from the phase 3 SURPASS program were evaluated post hoc by trial. Participants with T2D were randomized to tirzepatide (5, 10, and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2), or titrated basal insulin (SURPASS-3,4). The proportions of participants achieving the composite endpoints were compared between tirzepatide and the respective comparator groups at week 40/52.The proportions of participants achieving an HbA1c value of7.0% with ≥5% weight loss and without hypoglycemia ranged from 43% to 82% with tirzepatide across the SURPASS-1 to -5 trials versus 4%-5% with placebo, 51% with semaglutide 1 mg, and 5% with basal insulin (p0.001 versus all comparators). The proportions of participants achieving an HbA1c value of7.0% with ≥10% or ≥15% weight loss and without hypoglycemia were significantly higher with all tirzepatide doses versus comparators across trials (p0.001 or p0.05). Similar results were observed for all other combinations of endpoints with an HbA1c value of ≤6.5% or5.7%, with more tirzepatide-treated participants achieving these endpoints versus those in the comparator groups, including semaglutide.Across the SURPASS-1 to -5 clinical trials, more tirzepatide-treated participants with T2D achieved clinically meaningful composite endpoints, which included reaching glycemic targets with various degrees of weight loss and without hypoglycemia, than those in the comparator groups. This article is protected by copyright. All rights reserved. |
Plný text